Acumen Pharmaceuticals Inc

NASDAQ:ABOSUnited States

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in clinical development following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to Alzheimer’s pathology). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The Company is developing sabirnetug for intravenous (IV), administration every four weeks for the treatment of early AD.

Contact Information

Headquarters

427 PARK ST.CHARLOTTESVILLE, VA, United States 22902

Phone

925-368-8508

Fax

302-636-5454

Executives

President, Chief Development Officer

James Doherty

Chief Executive Officer, Director

Daniel O'Connell

Co-Founder, Chief Scientific Advisor

Grant Krafft

Chief Financial Officer, Chief Business Officer

W. Matthew Zuga

Chief Operating Officer

Russell Barton